The apelin/APJ system as a therapeutic target in metabolic diseases
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Apelin, a bioactive peptide, is the endogenous ligand of APJ, a G protein-coupled receptor which is widely expressed in peripheral tissues and in the central nervous system. The apelin/APJ system is involved in the regulation of various physiological functions and is a therapeutic target in different pathologies; the development of APJ agonists and antagonists has thus increased. Area covered: This review focuses on the in vitro and in vivo metabolic effects of apelin in physiological conditions and in the context of metabolic diseases. Expert opinion: In experimental models, novel APJ agonists are efficient in vivo, to treat metabolic diseases and associated complications. However, more clinical trials are necessary to determine whether molecules that target APJ could become an alternative therapeutic strategy in the treatment of metabolic diseases and associated complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity
Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigné, C., Mazzucotelli, A., Castan-Laurell, I., Tack, I., Knibiehler, B., Carpéné, C., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1427 · Cited by 910
Self-citationUpdate on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647 · cited 2×
“receptor agonists, insulin-sensitizing drugs (for review see [19]).”
BackgroundThiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518
The exerkine apelin reverses age-associated sarcopenia
Vinel, C., Lukjanenko, L., Batut, A., Deleruyelle, S., Pradère, J.-P., Le Gonidec, S., Dortignac, A., Geoffre, N., Pereira, O., Karaz, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0131-6 · Cited by 398
Self-citationJakobsen, S. N., Hardie, D. G., Morrice, N., & Tornqvist, H. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100483200 · Cited by 238 · cited 14×
“Apelin-induced activation of AMPK in different tissues has strengthened its therapeutic potential.”
BackgroundInfluentialZhang, X., Ye, Q., Gong, D., Lv, Y., Cheng, H., Huang, C., Chen, L., Zhao, Z., Li, L., Wei, X., et al. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx038 · Cited by 47
Cited by
Targeting the apelin system for the treatment of cardiovascular diseases
Chapman, F. A., Maguire, J. J., Newby, D. E., Davenport, A. P., & Dhaun, N. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad171 · Cited by 104
“A full review of apelin’s metabolic effects has been described recently (see tan-Laurell et al. 149 ).”
BackgroundWang, Q., Cheng, S., Qin, F., Fu, A., & Fu, C. (2021) · RSC Advances · doi:10.1039/d1ra00550b · Cited by 85
Exercise Training Modulates Adipokine Dysregulations in Metabolic Syndrome
Babaei, P., & Hoseini, R. (2022) · Sports Medicine and Health Science · doi:10.1016/j.smhs.2022.01.001 · Cited by 52
Metadata
- Authors
- Castan-Laurell, I., Masri, B., & Valet, P.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2019-01-10
- Volume
- 23
- Issue
- 3
- Pages
- 215-225
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2906138479
- Cited by
- 54
- References
- 6
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The apelin/APJ system as a therapeutic target in metabolic diseases. https://app.cochat.ai/papers/10.1080/14728222.2019.1561871
- The paper
- Castan-Laurell, I., Masri, B., & Valet, P. (2019). The apelin/APJ system as a therapeutic target in metabolic diseases. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2019.1561871
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.